Cantargia presents promising early results with nadunolimab in MDS and AML ahead of ASH 2026

Cantargia presented promising early results with nadunolimab in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) ahead of ASH 2026.

Detected & updated continuously · Source: Nebula